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Novelty statement 
 This updated meta-analysis only suggests a modest benefit of aspirin in the prevention 
of major adverse cardiovascular events (MACE) in people with diabetes.   
 Limited subgroup analyses suggest differences in the effect of aspirin by baseline 
CVD risk, medication compliance, and sex on MACE. 
 The overall evidence does not clearly support guidelines that encourage the use of 
aspirin for the primary prevention of CVD in adults with diabetes who are at increased 
CVD risk 
 
  
Abstract 
Aims We sought to evaluate the benefits and harms of aspirin for the primary prevention of CVD and 
all-cause mortality events in people with diabetes by conducting a systematic review and meta-
analysis. 
Methods Randomised controlled trials of aspirin compared with placebo (or no treatment) in people 
with diabetes with no previous history of CVD were identified from MEDLINE, EMBASE, Web of 
Science, Cochrane Library, and manual search of bibliographies to November 2015. Study specific 
relative risks with 95% CIs were aggregated using random effects models.  
Results Ten randomised trials were included. Comparing aspirin with placebo (or no treatment), there 
was a significant reduction in risk of major adverse cardiovascular events (MACE) 0.90 (0.81-0.99). 
Limited subgroup analyses suggested differences in the effect of aspirin by baseline CVD risk, 
medication compliance, and sex on MACE (P for interaction for all > 0.05).There was no significant 
reduction in the risk of myocardial infarction (MI), coronary heart disease, stroke, cardiovascular 
mortality, or all-cause mortality. Aspirin significantly reduced the risk of MI for a treatment duration 
of five years or less. There were differences in the effect of aspirin by dosage and treatment duration 
on overall stroke outcomes (P for interaction for all < 0.05). There was an increase in risk of major or 
gastrointestinal bleeding events, but estimates were imprecise and not significant. 
Conclusions New emerging data do not clearly support guidelines that encourage the use of aspirin 
for the primary prevention of CVD in adults with diabetes who are at increased CVD risk.  
 
Systematic review registration: PROSPERO 2015: CRD42015026321 
 
Keywords aspirin, diabetes, primary prevention, cardiovascular disease, meta-analysis 
 
 
 
 
 
Introduction 
Individuals with diabetes have a two-to-four fold increased risk of developing vascular events.(1) 
Cardiovascular disease (CVD) is the leading cause of mortality in people with diabetes, accounting 
for more than 70% of deaths in these people.(2) This has led to increasing interest over recent decades 
to develop interventions aimed at reducing cardiovascular risk in people with diabetes. In diabetes, 
there are several abnormalities in platelet function,(3) leading to an accelerated state of atherosclerosis 
and inflammation which promotes vascular complications.(4) Given this, interventions that inhibit 
platelet activation and aggregation, such as aspirin therapy, have been proposed as key therapeutic 
strategies to reduce ischaemic risk in people with diabetes.(4) Low-dose aspirin has been used for 
many decades in the treatment and prevention of CVD. The effectiveness of aspirin in people with 
diabetes for the secondary prevention of CVD is well established.(5) A number of randomised 
controlled trials (RCTs) have reported on the role of aspirin for the primary prevention of CVD in 
people with diabetes, but, majority of these studies were often poorly powered with regard to the 
number of people with diabetes, reported results from subgroups, and have reported conflicting 
results. Since the publication of the meta-analysis of individual-level data from six primary prevention 
trials by the Antithrombotic Treatment Trialists’ Collaboration in 2009, which reported a non-
significant reduction in serious vascular events in people with diabetes;(6) several other meta-analyses 
have been conducted on the topic and reported no significant benefit for aspirin in primary prevention 
of cardiovascular disease in people with diabetes.(7-10) 
Consistent with the uncertain evidence, recent guidelines of the Fifth Joint Task Force of the 
European Society of Cardiology and Other Societies on CVD Prevention in Clinical Practice do not 
provide specific recommendations for the use of aspirin in people with diabetes.(11) In contrast, 
guidelines by the American Diabetes Association (ADA), the American Heart Association (AHA), 
and the American College of Cardiology Foundation (ACCF) advocate for the use of low-dose aspirin 
for the primary prevention of CVD in adults with diabetes, but which should be based on the 
individual risk for CVD and risk for bleeding.(8) These recommendations were based on pooled 
analysis of nine trials which suggested a modest reduction (albeit precludes a precise estimate of the 
effect size) in risk of cardiovascular events with the use of aspirin. Given the uncertain role of aspirin 
in primary prevention of CVD in people with diabetes, the guideline authors cite ongoing studies 
which will add important new information in this area. The ASCEND (A Study of Cardiovascular 
Events iN Diabetes) randomised trial which has recruited over 15,000 patients, may provide reliable 
evidence about the effects of low-dose aspirin for the prevention of cardiovascular events in people 
with diabetes, but the follow up is not due to end until 2017.(12) Given the high clinical interest of 
this topic and with the publication of newer trials since the last relevant meta-analysis on the topic, we 
aimed to address the persisting uncertainties on the benefits and harms of aspirin for the primary 
prevention of CVD and all-cause mortality events in people with diabetes by conducting an updated 
systematic meta-analysis. We also sought to compare the effectiveness of aspirin with placebo (or no 
treatment) for the primary prevention of CVD and all-cause mortality events in people with diabetes, 
under a range of relevant clinical characteristics such as baseline CVD risk, dosage of aspirin, 
compliance, and treatment duration. 
 
Methods 
Data sources and search strategy  
We conducted this review using a predefined protocol, which has been registered in the PROSPERO 
prospective register of systematic reviews (CRD42015026321), and in accordance with PRISMA 
guidelines (Appendix 1).(13) Two independent authors, in duplication, sought randomised controlled 
trials published before November, 2015 (date last searched) using MEDLINE, EMBASE, Web of 
Science, and the Cochrane electronic databases. The computer-based searches combined terms related 
to (1) the intervention, aspirin (e.g., aspirin, salicylic acid, and salicylates) and (2) diabetes (e.g., 
diabetes mellitus, type 2 diabetes, and type 1 diabetes) or primary prevention (e.g., primary 
prevention) in humans, without any language restriction. Details on the search strategy are provided in 
Appendix 2. Two independent reviewers screened the titles and abstracts of all initially identified 
studies according to the selection criteria. Full texts were retrieved from studies that satisfied all 
selection criteria. Reference lists of selected studies and relevant reviews identified on the topic were 
searched for additional publications.  
 
Study selection and eligibility criteria  
Intervention studies were sought that had reported on the use of aspirin for the primary prevention of 
CVD in diabetes mellitus and reported data on a variety of cardiovascular and all-cause mortality 
endpoints. Intervention studies were eligible if they were randomised controlled, open or blinded trials 
(1) that assessed the effects of aspirin therapy compared to a placebo or no treatment; (2) which 
enrolled adults (≥ 18 years old) with diabetes mellitus (either exclusively or as a subgroup) without 
previous history or clinical evidence of CVD; and (3) and had a follow-up duration of at least 12 
months. Studies were excluded if they were non-randomised comparing aspirin with another 
antiplatelet agent, included people with known CVD, or were secondary publications of trials already 
included in the analysis.   
 
Data extraction  
Two independent authors (SKK and SS) extracted data and a consensus was reached in case of any 
inconsistency with involvement of a third (KK). A predesigned data extraction form was used to 
obtain relevant information. These included, where appropriate, study-level information on study 
design; baseline population including proportion of men; location; average age at baseline; numbers 
enrolled and randomised; allocation concealment; blinding; intervention and dosage; medication 
compliance; duration of treatment or follow-up; treatment comparisons; outcomes of major adverse 
cardiovascular events (MACE) [defined as composite of nonfatal myocardial infarction (MI), nonfatal 
stroke, and cardiovascular death], other cardiovascular outcomes, all-cause mortality, and adverse 
events; and risk estimates for each outcome of interest.  
 
Assessing the Risk of Bias  
Two reviewers independently rated the methodological quality of the studies using the Cochrane 
Collaboration’s risk of bias tool(14) and a consensus was reached with involvement of a third 
reviewer. This tool, which is well known and widely accepted for assessing the validity of randomised 
trials, evaluates seven possible sources of bias: random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, 
selective reporting and other bias. For each individual domain, studies were classified into low, 
unclear and high risk of bias.  
 
Statistical analysis  
Summary measures were presented as relative risks (RRs) with 95% confidence intervals (CIs). We 
assumed hazard ratios and odds ratios to approximate the same measure of RRs. We used reported 
RRs or calculated study specific unadjusted RRs based on event rates. When studies published more 
than one RR estimate according to event subtypes (e.g., fatal and nonfatal MI), a within-study 
summary estimate for the composite event (e.g. MI) was obtained using a fixed effect analysis. For 
three trials that did not report data on the subset of participants with diabetes,(15-17) we extracted 
these data from previous reports.(8) The inverse variance weighted method was used to combine 
summary measures using random-effects models to minimise the effect of between-study 
heterogeneity. Subsidiary analyses employed fixed effects models. Statistical heterogeneity across 
studies was quantified using the Cochrane χ2 statistic and the I2 statistic.(18) Study level 
characteristics including geographical location, allocation concealment, baseline CVD risk, dose of 
aspirin, compliance, duration of treatment, number of outcomes, and sex differences were 
prespecified as characteristics for assessment of heterogeneity, which was conducted using stratified 
analysis and random effects meta-regression. We assessed the potential for small study effects such as 
publication bias through formal tests, namely Begg’s funnel plots and Egger’s regression symmetry 
tests.(19) To contextualise our results, we also calculated the number needed to treat (NNT) using the 
formula: NNT = 1 / absolute risk reduction (ARR). The ARR was derived by calculating the 
difference between the rate of events in the control group and the intervention group. STATA release 
14 (StataCorp LP, College Station, TX, USA) software was used for all statistical analyses. 
 
Results 
Study identification and selection  
Our initial search of relevant databases and manual scanning of reference lists identified 3,586 
potentially relevant citations. After screening based on titles and abstracts, 13 articles remained for 
further evaluation. Following detailed assessments, three articles were excluded. The remaining 10 
articles based on 10 unique studies met our inclusion criteria and were included in the review 
(Appendix 3; Fig. 1).  
 
Study characteristics and quality  
Table 1 summarises the key characteristics of the randomised trials included in the review. In 
aggregate, the included trials published between 1988 and 2014, comprised 16,690 participants with 
diabetes. The majority (n=six) of trials were double-blinded and four were open label trials. Four of 
the trials were conducted in Europe (UK and Italy); three in North America (USA); two in Asia 
(Japan); and one recruited patients from 26 countries in Europe, North and South America, and Asia. 
The baseline age of participants ranged from 18 to 90 years. There was considerable variability in 
study populations which included healthy participants, participants with pre-existing conditions such 
as hypertension, as well as participants at high cardiovascular risk. Three trials were conducted 
specifically in people with diabetes and the seven others were based on data from subgroups of people 
with diabetes. Only one trial made a distinction between type 1 and type 2 diabetes in their results and 
also included a small proportion of people with pre-existing CVD.(20) The dosage of aspirin ranged 
from 75 mg to 650 mg daily and the duration of therapy ranged from 3.6 to 10.1 years. Medication 
compliance was reported in five trials using a variety of subjective (self-reports) and objective 
(biochemical monitoring and pill counts) measures. Six trials demonstrated a high risk of bias within 
one or two areas of study quality, as assessed using the Cochrane Collaboration tool (Appendix 4). 
Majority of the trials had a high risk of bias for selective reporting. Only one trial was found to have a 
low risk of bias in all areas and seven trials had an unclear risk of bias in one or more areas of study 
quality. 
 
Major cardiovascular outcomes and all-cause mortality  
Fig. 2 and Appendices 6-11 presents RRs for cardiovascular outcomes and all-cause mortality events 
for aspirin therapy compared with placebo or no treatment in trials contributing to pooled analyses. 
Seven trials comprising of 15,988 participants reported on MACE (1,543 events). A significant 
reduction in risk of MACE was found with aspirin compared with placebo or no treatment 0.90 (95% 
CI: 0.81 to 0.99; p=0.031). The pooled RR remained unchanged using a fixed effects model 
(Appendix 5). There was no evidence of heterogeneity between the contributing studies (I2=0%, 0 to 
71%; p=0.989). When the Early Treatment Diabetic Retinopathy Study (ETDRS), the trial that 
involved a small proportion of patients with previous CVD, was excluded from the analysis, the 
pooled RR was 0.90 (95% CI: 0.78 to 1.02; p=0.106). 
Aspirin therapy was not associated with a significant reduction in risk of MI (seven trials 
comprising of 11,618 participants and 879 events) 0.84 (95% CI: 0.64 to 1.11; p=0.225) or CHD (five 
trials comprising of 5,485 participants and 312 events) 0.98 (95% CI: 0.79 to 1.21; p=0.747). There 
was evidence of moderate heterogeneity (I2=57%, 1 to 82%; p=0.029) for the MI analysis and no 
evidence of heterogeneity (I2=0%, 0 to 79%; p=0.747) for the CHD analysis. 
Eight trials comprising of 11,254 participants found no significant reduction in risk of stroke 
events with aspirin 0.86 (95% CI: 0.69 to 1.08; p=0.226) and there was evidence of low heterogeneity 
between the contributing studies (I2=20%, 0 to 62%; p=0.272). 
No significant reduction in risk of CVD mortality with aspirin compared with placebo or no 
treatment was found (five trials comprising of 10,058 participants and 675 events) 0.94 (95% CI: 0.71 
to 1.26; p=0.228). There was evidence of low heterogeneity (I2=38%, 0 to 77%; p=0.166).  
Aspirin therapy was not associated with a significant decrease in risk of all-cause mortality (five 
trials comprising of 10,058 participants and 1,094 events) 0.94 (95% CI: 0.83 to 1.05; p=0.280) and 
there was no evidence of heterogeneity between contributing studies (I2=0%, 0 to 79%; p=0.807). 
 
Other cardiovascular outcomes  
Aspirin therapy compared with placebo or no treatment, was not associated with a significant 
reduction in risk of other cardiovascular outcomes such as nonfatal MI, CHD death, fatal stroke, 
nonfatal stroke, ischaemic stroke, haemorrhagic stroke, CVD, revascularization, angina pectoris, TIA, 
and sudden coronary death (Fig. 3; Appendix 11). 
 
 
Subgroup analysis  
For MACE, there was no statistically significant evidence of effect modification by several clinically 
relevant characteristics. However, compared to people with high CVD risk, participants with low 
CVD risk had a significantly reduced risk of MACE with aspirin (p-value for meta-regression = 
0.616) and people who were ≥ 90% compliant showed a significant reduction in risk of MACE with 
aspirin therapy compared to those who were < 90% compliant (p-value for meta-regression = 0.616) 
(Fig. 4).  In addition, stratified analysis by sex showed that aspirin significantly reduced the risk of 
MACE in men 0.79 (95% CI: 0.64 to 0.98; p=0.033) but not in women 0.95 (95% CI: 0.77 to 1.16; 
p=0.591) (p value for meta-regression = 0.437). 
For MI, the moderate heterogeneity was partly explained by treatment duration (p value for meta-
regression = 0.012). Compared to participants with treatment duration more than five years, 
participants with treatment duration of five years or less had a significantly reduced risk of MI with 
aspirin 0.70 (95% CI: 0.53 to 0.93; p=0.012) (Appendix 12). There was no evidence of effect 
modification by sex. In further exploration of heterogeneity, exclusion of the Women’s Health Study 
(WHS) and the Physicians’ Health Study (PHS) substantially reduced heterogeneity to (I2=23%, 95% 
CI 0 to 82%; p=0.270) and the pooled estimate 0.87 (95% CI: 0.71 to 1.06; P=0.176) was similar to 
the main finding. 
For stroke, there was evidence of effect modification by aspirin dosage (p value for meta-
regression = 0.019) and treatment duration (p value for meta-regression = 0.026). The risk of stroke 
was significantly reduced for trials using aspirin dosage of 100 mg per day or less compared to more 
than 100 mg per day. Similarly, compared to participants with treatment duration of five years or less, 
participants with treatment duration of more than five years had a significantly reduced risk of stroke 
with aspirin (Appendix 13). There was no evidence of effect modification by sex. 
There was no evidence of effect modification by any of the covariates explored for the outcomes 
of CVD death and all-cause mortality (Appendices 14-15). No evidence of effect modification by sex 
was found for both outcomes. 
 
 
Adverse effects  
Fig. 5 presents RRs of the effects of aspirin therapy compared with placebo or no treatment on any 
and gastrointestinal bleeding, non-gastrointestinal bleeding, gastrointestinal symptoms, cancer, 
arrhythmias, and allergy. There was no significant increase in risk of any of these adverse events.  
 
Absolute benefit and harm  
For the primary analysis, the absolute risk reduction of major adverse cardiovascular events in people 
with diabetes associated with aspirin therapy was 0.92% which translates into a NNT of 109 to 
prevent one major adverse cardiovascular event.  
 
Publication bias  
Under visual examination, funnel plots for those analyses that involved five or more studies were 
mostly symmetrical and Egger’s regression tests showed no statistical evidence of publication bias for 
all analyses (Appendix 16). In addition, we found no definitive evidence of selective reporting when 
studies were grouped by size in meta-regression analyses (Fig. 4; Appendices 12-15). 
 
Discussion 
Key findings 
We have systematically summarised through a meta-analytical approach, available randomised 
controlled trials that have assessed the role of aspirin for the primary prevention of CVD and all-cause 
mortality events among people with diabetes. We found a modest and significant reduction (10%) in 
the risk of MACE with aspirin therapy compared with placebo or no treatment. The modest reduction 
however lost significance when the ETDRS trial was excluded. There was no significant reduction in 
the risk of individual cardiovascular endpoints as well as all-cause mortality. Except for MI, there was 
no or low heterogeneity in analyses of relevant outcomes. In stratified analyses, there were 
suggestions of differences in the effect of aspirin by baseline CVD risk, medication compliance, and 
sex on MACE. However, given that there was no statistically significant evidence of effect 
modification in these stratified analyses, the results should be interpreted with caution. For all other 
specific endpoints explored, there was no significant reduction in risk with aspirin therapy in men or 
women. Aspirin significantly reduced the risk of MI by 30% for a treatment duration of five years or 
less, with no benefit for treatment duration of more than five years. In addition, the risk of stroke was 
significantly reduced for trials with lower intervention doses and longer average intervention periods. 
For the effects of aspirin therapy on adverse-events, there was suggestion of increased risk of bleeding 
and gastrointestinal symptoms with aspirin therapy in people with diabetes, but the estimates were 
imprecise and not significant. Pooled analysis of two trials suggested a protective effect of aspirin 
therapy on cancer outcomes, but this was not significant.  
 
Comparison with previous work 
Some of our findings generally concur with that of previous reviews on the topic. We also provide 
several relevant findings that have not been previously reported. In contrast to previous reviews, we 
found a modest- sized reduction in MACE which was statistically significant and based on pooled 
analysis of seven trials in our primary analysis. De Berardis et al(9) and Butalia et al(7) in pooled 
analyses of five and six trials respectively, found no significant reduction in the risk of MACE with 
aspirin therapy compared with placebo or no treatment; however, their pooled estimate verged on 
statistical significance. Zhang and colleagues in pooled analysis of six trials showed an 8% reduction 
in MACE which was not statistically significant.(10) Furthermore, our analyses provided suggestions 
of differences in the effect of aspirin by baseline CVD risk, compliance, and sex for MACE (albeit p 
values for meta-regression > 0.05). For the effects of aspirin therapy on specific cardiovascular 
endpoints and all-cause mortality, our non-significant estimates of effect are consistent with previous 
reviews on the topic.(7-10) Our analyses were characterised by no or low heterogeneity between 
contributing studies; except for evidence of moderate heterogeneity in the MI analysis, which was 
mainly due to the inclusion of the WHS and PHS and which was also demonstrated by De Berardis et 
al(9) and Pignone et al.(8) In contrast to our findings, De Berardis et al(9) and Pignone et al.(8) also 
identified moderate heterogeneity in the stroke analyses. In subgroup analyses involving eight stroke 
trials, we found evidence of effect modification by aspirin dosage and treatment duration, consistent 
with that of De Berardis and colleagues who pooled five trials.(9) Our findings also demonstrated 
effect modification by treatment duration for MI outcomes, but no important differences by sex, 
which was identified by De Berardis et al(9) and Zhang et al.(10) Consistent with Butalia et al(7) and 
Zhang et al(10), we found no evidence of publication bias in our analyses.  We additionally grouped 
studies by size and found no evidence of selective reporting. 
 
Possible explanations for findings 
We demonstrated a significant but modest benefit of aspirin in the primary prevention of MACE in 
our meta-analysis which was coherent with that observed in other high risk populations,(6, 21) but in 
contrast to the non-significant reduction demonstrated in several previous reviews. Our results may 
appear at first to be at odds with previous reports on the topic, but this is not quite the case. The effect 
estimates and confidence intervals reported in previous reviews are consistent with a potential benefit 
of aspirin, but were not significant or were on the verge of significance. As discussed by De Berardis 
and colleagues,(9) this could be due to low power to detect an effect. We pooled the results of seven 
trials of MACE resulting in a higher number of events compared to previous reviews, therefore the 
possibility of enhanced power to show a significant risk reduction in MACE. However, the results 
were not statistically significant on excluding the ETDRS trial.(20) Given that this study, which was 
the largest trial in our study in terms of event rate, the non-significant results on exclusion could 
indicate loss of power. Indeed, De Berardis and colleagues,(9) demonstrated no material effect in their 
results when the ETDRS trial was excluded from their pooled analysis of only five trials of MACE. 
We were unable to show a significant reduction in the risk of other specific cardiovascular endpoints 
and all-cause mortality, which were consistent with findings from previous reviews. Taking our 
overall findings and that of previous reviews together, there is a possibility that aspirin may have a 
beneficial but modest effect in the primary prevention of cardiovascular disease in people with 
diabetes, but the current evidence is not conclusive.  Previous studies have interpreted the data to 
indicate low efficacy of aspirin in people with diabetes.(9, 10) Several plausible mechanisms have 
been postulated for a lower efficacy of aspirin in people with diabetes. Aspirin resistance has been 
suggested to be a contributing factor for the low efficacy of or poor response to aspirin therapy. 
People with diabetes have altered platelet function, have abnormalities in endothelial and vascular 
smooth muscle cell functions, and have increased production of prothrombotic clotting factors and 
proinflammatory markers,(22-24) which all contribute to the capacity to diminish the effects of 
aspirin on platelet function.(25)  The prothrombotic and proinflammatory states have been suggested 
to result in failure of aspirin to modify platelet response and with little effect on thrombus 
formation.(23) Hyperglycaemia, which is associated with diabetes, may interfere with the acetylation 
process which contributes to increased aspirin resistance.(26) Other factors specific to diabetes, such 
as hyperlipidaemia, hypertension, and hyperinsulinaemia, have also been suggested to be involved in 
aspirin resistance.(24, 27) 
We found differences in the effect of aspirin by treatment duration on MI and stroke. Whiles 
aspirin reduced the risk of MI for shorter average intervention periods, the risk was reduced for stroke 
in longer average intervention periods. Given that these vascular outcomes have somewhat diverse 
aetiology,(28) these findings may reflect a true differential effect. In addition, we observed a 
difference in the effect of aspirin by dosage on stroke. However, the differences seen in the effect of 
aspirin by treatment duration and dosage is potentially misleading, as stroke outcome was a combined 
endpoint of stroke subtypes (e.g. haemorrhagic and ischaemic stroke), which have different 
aetiologies. Given that aspirin is known to have a differential effect on these stroke subtypes [aspirin 
is used as first line antiplatelet drug for the secondary prevention of ischaemic stroke (29) and 
contraindicated in patients who have had a haemorrhagic stroke] and the limited number of studies 
available for such subgroup analyses, these findings may have arisen from the effects of low statistical 
power or chance. We were unable to conduct separate analyses for the subtypes of stroke because of 
the limited amount of data. Therefore, these results may require replication in further studies. 
 
Implications of our findings 
Our findings are relevant, provide further insight on aspirin therapy in primary cardiovascular 
prevention therapy in diabetes, and may have implications for clinical practice. Aspirin may have a 
beneficial effect on the prevention of major adverse cardiovascular events in people with diabetes 
(relative risk reduction of 10%) and may have specific effects by baseline CVD risk, compliance, and 
gender. Our absolute risk reduction based on our primary analyses translates to about 1,000 people 
that need to be treated to prevent one major adverse cardiovascular event in a year. The main adverse 
effects of aspirin therapy appear to be gastrointestinal bleeding, which have been based mainly on 
data from general and secondary prevention populations.(21) An absolute excess of gastrointestinal 
bleeding complications have been demonstrated in these populations with both low dosage and long 
term aspirin therapy.(30) A higher risk of bleeding events has been reported among people at low 
cardiovascular risk and the elderly.(31) However, we and others have not been able to demonstrate 
this in primary prevention populations with diabetes. Nonetheless, data from real-world settings in 
general populations suggest higher rates of bleeding in people with diabetes on aspirin therapy.(32) 
Given the overall evidence and the imprecise estimates reported, these results may mainly be due to 
inadequate power of these trials to detect these events. Before any guideline recommendations should 
be made, the benefits of aspirin on CVD in primary prevention populations with diabetes need to be 
balanced against the potential for harm. Given our absolute risk reduction estimates and the potential 
for an increased risk of major bleeding events, it is likely that the benefits might not exceed the harms. 
Recent guidelines by the ADA recommend the use of low-dose aspirin (75-162 mg/day) for the 
primary prevention of CVD in adults with type 1 and 2 diabetes who are at increased CVD risk (10 
year risk more than 10%), whilst not recommended for people at low CVD risk (10 year risk less than 
5%).(33) However, given the current data, the use of aspirin for the primary prevention of 
cardiovascular events in people with diabetes at increased CVD risk cannot be justified. Our review 
also suggested a protective effect of aspirin therapy on cancer outcomes, but this was based on pooled 
results of two trials and the estimate was not significant. Given that type 2 diabetes is known to be 
associated with an increased risk of colorectal carcinomas,(34) these findings are of interest. The role 
of the potential prevention of cancer with aspirin therapy is of emerging interest especially in people 
with type 2 diabetes and is a topic for further investigation. 
Our updated study also highlights the existing scientific gaps in trial evidence, which stimulates 
the need for further research. There may be important differences in the effect of aspirin by treatment 
dosage and compliance, treatment duration, and sex, but the findings from our study and that of 
previous reviews have mostly been mixed, due to aggregation of insufficiently powered studies and 
reporting of results from subgroup analyses. Carefully designed RCTs with large-sample sizes 
involving individuals with diabetes are warranted to evaluate the role of aspirin in the primary 
prevention of cardiovascular events in people with diabetes. Quoting previous reviews on this 
extensively researched but unresolved topic,(8, 9) two on-going trials, A Study of Cardiovascular 
Events in Diabetes (ASCEND; International Standard Randomized Controlled Trial Number 
ISRCTN60635500)(12)  and the Aspirin and Simvastatin Combination for Cardiovascular Events 
Prevention Trial in Diabetes (ACCEPT-D, Current Controlled Trials ISRCTN48110081),(35) are 
expected to enrol more than 15,000 people with diabetes and may help address the existing 
inconsistencies. 
 
Strengths and limitations 
The current study has several advantages compared to previous reviews. It is a comprehensive, 
updated assessment and the largest meta-analysis on the topic to date. The generalisability of our 
findings were enhanced by the involvement of data from 10 trials which included 16,690 people with 
diabetes and therefore the ability to examine the efficacy of aspirin therapy on a wider range of 
cardiovascular endpoints, as well as adverse events including arrhythmias, cancer, and allergy. We 
also conducted detailed analyses under a broader range of individual and study-level circumstances 
which included sample size, geographical location, and baseline CVD risk. Formal tests were unable 
to detect publication bias for all analyses. There was evidence of no or low heterogeneity among 
contributing studies for the majority of the analyses. For the only analysis that involved moderate 
heterogeneity (MI outcome), we systematically explored possible sources of heterogeneity using 
stratified and meta-regression analyses. There are also several limitations of this review and meta-
analysis which deserve consideration. Though the meta-analysis was very comprehensive, it was 
based on a limited number of published studies, which precluded the ability to perform clinically 
relevant subgroup analyses (eg, baseline age, appropriate baseline CVD risk groups, appropriate 
treatment dosages, type of diabetes, duration of diabetes, etc). Results for several cardiovascular 
outcomes were based on pooled estimates of only up to three studies.  The new trial included in our 
updated review only contributed to the pooled estimate of MACE. As with aggregate reviews, the 
definitions of some of the clinical outcomes as well as secondary endpoints such as medication 
compliance were not consistent across all studies, which could potentially have led to biased 
estimates. There appeared to be selective reporting bias, as data on some cardiovascular endpoints and 
adverse events were not reported by some of the included studies. Pooled estimates for adverse events 
were based on the limited amount of data reported by eligible trials and were imprecise. Given the 
limitations, the findings should be interpreted with caution and intensify the need for detailed future 
intervention studies and individual patient data meta-analysis to help clarify any beneficial role of 
aspirin in primary prevention. 
 
Conclusions  
New emerging data suggests a modest potential benefit of aspirin in the primary prevention of major 
adverse cardiovascular events in people with diabetes. There were suggestions of differences in the 
effect of aspirin by baseline CVD risk, compliance, and sex on major adverse cardiovascular events. 
The current data does not clearly support guidelines that encourage the use of aspirin for the primary 
prevention of CVD in adults with diabetes who are at increased CVD risk. Additional evidence is 
required. 
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Figure 2: Effect of aspirin on the primary prevention of major adverse cardiovascular events, 
myocardial infarction, coronary heart disease, stroke, cardiovascular disease death, and all-cause 
mortality in people with diabetes 
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CI, confidence interval (bars); RR, relative risk 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Effect of aspirin on the primary prevention of individual cardiovascular disease endpoints 
in people with diabetes 
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Figure 4: Effect of aspirin on the primary prevention of major adverse cardiovascular events in 
people with diabetes, grouped according to several study characteristics 
Location
Europe
North America
Other
Allocation concealment
Adequate
Unclear
Baseline CVD risk
High risk
Low risk
Aspirin dose (mg/day)
> 100
≤ 100
Compliance (%)
≥ 90
< 90
Treatment duration (years)
> 5
≤ 5
No. of events
> 150
≤ 150
Subgroup
125 / 1,157
408 / 2,370
201 / 4,459
326 / 5,616
408 / 2,370
211 / 3,602
523 / 4384
350 / 1,856
384 / 6,130
523 / 4,384
211 / 3,602
249 / 3,597
485 / 4,389
609 / 6,201
125 / 1,785
Aspirin
Events / Participants
130 / 1,150
441 / 2,368
238 / 4,484
368 / 5,634
441 / 2,368
228 / 3,608
581 / 4,394
379 / 1,855
430 / 6,147
581 / 4,394
228 / 3,608
268 / 3,609
541 / 4,393
671 / 6,228
138 / 1,774
Placebo or control
Events / Participants
0.96 (0.77, 1.20)
0.90 (0.79, 1.03)
0.85 (0.71, 1.03)
0.90 (0.78, 1.03)
0.90 (0.79, 1.03)
0.93 (0.78, 1.12)
0.88 (0.79, 0.99)
0.90 (0.78, 1.04)
0.90 (0.78, 1.02)
0.88 (0.79, 0.99)
0.93 (0.78, 1.12)
0.93 (0.79, 1.10)
0.88 (0.78, 1.00)
0.90 (0.81, 1.00)
0.89 (0.70, 1.13)
RR (95% CI)
.736
.956
.616
.962
.616
.626
.922
P-value*
Favours aspirin  Favours control or placebo 
1.5 1.5 2.5
 
CI, confidence interval (bars); *, P-value for meta-regression 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Effect of aspirin on adverse events in people with diabetes 
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Table 1: Characteristics of clinical trials of aspirin therapy included in meta-analysis 
Lead Author, 
Publication 
Date  
 
Name of study 
or source of 
participants 
 
 
 
 
 
 
 
 
 
 
 
 
Study design 
 
 
 
 
 
 
 
 
 
 
 
 
Patient population 
 
 
 
Location 
 
 
 
 
 
 
 
 
 
 
Baseline 
year of 
study 
 
 
 
 
 
 
 
 
 
 
 
Age 
group 
Males 
(%) 
 
Allocation 
concealment 
 
 
Blinding 
to 
subjects 
 
 
 
Blinding to 
carers 
 
Aspirin 
dose 
 
 
 
 
 
 
 
 
 
 
Medication 
compliance 
(%) 
 
 
 
 
 
 
 
 
 
 
Duration of 
therapy 
(years) 
 
 
Completeness 
of follow-up 
 
 
 
Trial 
participants 
with diabetes 
Peto, 1988 BMD Randomised, open label 
with no placebo 
Healthy male doctors UK 1978-1979 19-90 100.0 No No No 500 mg daily NR 5.6 Unclear 101 
PHS Steering 
Committee, 
1989 
PHS RCT, double blinded Healthy men USA 1982 40-84 100.0 Unclear Yes Yes 325 mg every 
other day 
NR 5.0 99.7 533 
ETDRS 
Investigators, 
1992 
ETDRS RCT, double blinded Participants with type 1 and 
2 diabetes 
USA 1980-1985 18-70 56.5 Unclear Yes Yes 650 mg daily 91.8 5.0 94.7 3,711 
MRC, 1998 TPT Randomized, placebo 
controlled. Factorial 
with initial parallel 
group phase 
Patients at high risk for IHD UK 1989-1994 45-69 100.0 Adequate Yes Yes 75 mg daily NR 6.7 98.9 68 
Hansson, 1998 HOT RCT, double blinded Participants with 
hypertension 
Multiple 
countries 
1992-1994 50-80 NR Adequate Yes Yes 75 mg daily NR 3.8 97.4 1,501 
Sacco, 2003 PPP Randomised open trial 
with 2 x 2 factorial 
design 
Participants > 50 years with 
one or more CV risk factors 
Italy NR 64.3* 48.2 Adequate No No 100 mg daily 71.8 3.6 99.3 1,031 
Ridker, 2005 WHS RCT, double blinded, 2 
x 2 factorial 
Healthy women USA 1993 ≥ 45 0.0 Unclear Yes Yes 100 mg on 
alternate days 
NR 10.1 99.4 1,027 
Belch, 2008 POPADAD RCT, double blinded, 2 
x 2 factorial 
Patients >=40 years with 
type 1  and 2 diabetes, ABP 
<=0.99 
Scotland NR ≥ 40 44.1 Adequate Yes Yes 100 mg daily 50.0 6.7 99.5 1,276 
Ogawa, 2008 JPAD Randomised open label 
with blinded end point 
assessment 
Patients with type 2 diabetes Japan 2002 65.0* 55.0 Adequate No No 81 or 100 mg 
daily 
90.0 4.4 92.4 2,539 
Ikeda, 2014 JPPP Randomised open label, 
parallel group 
Elderly with multiple 
atherosclerotic risk factors 
Japan 2005-2007 60-85 NR Adequate No No 100 mg daily 76.0 5.0 ~98.7 4,903 
 
*, average age; BMD, British male doctors; ETDRS, Early Treatment Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; IHD, ischaemic heart disease; JPAD, Japanese Primary Prevention of 
Atherosclerosis with Aspirin for Diabetes; JPPP, Japanese Primary Prevention Project; MRC, Medical Research Council; NR, not reported; PHS, Physicians’ Health Study; POPADAD, Prevention Of Progression of 
Arterial Disease And Diabetes; PPP, Primary Prevention Project; RCT, randomised controlled trial; UK, United Kingdom; USA, United States of America; WHS, Women’s Health Study 
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Appendix 1 PRISMA checklist 
 
Section/topic 
Item 
No Checklist item 
Reported on page 
No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study 
appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 3 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS) 4 
Methods 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information including 
registration number 
4 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication status) used as 
criteria for eligibility, giving rationale 
4 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last 
searched 
4 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated Appendix 2 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) 4-5 
Data collection process 10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from 
investigators 
5 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made 5 
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and 
how this information is to be used in any data synthesis 
5 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). 5-6 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) for each meta-analysis 5-6 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies) 6 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified 6 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram 6 and Figure 1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations 6-7, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). 7, Table 1 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect estimates and 
confidence intervals, ideally with a forest plot 
7-10 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency 7-10, Figures 2-5; 
Appendices 5-11 
Section/topic 
Item 
No Checklist item 
Reported on page 
No 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) 10, Appendix 4 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see item 16) Appendices 12-16 
Discussion 
Summary of evidence 24 Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as health care providers, 
users, and policy makers) 
10-11 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, reporting bias) 12-13 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research 13 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic review None 
Appendix 2 MEDLINE literature search strategy 
 
Relevant controlled trials, published from inception to November 10, 2015 (date last searched), were identified through 
electronic searches not limited to the English language using MEDLINE, EMBASE, Web of Science, and Cochrane databases. 
Electronic searches were supplemented by scanning reference lists of articles identified for all relevant studies (including review 
articles), and by hand searching of relevant journals. The computer-based searches combined search terms related to (1) the 
intervention, aspirin (e.g., aspirin, salicylic acid, and salicylates) and (2) diabetes (e.g., diabetes mellitus, type 2 diabetes, and 
type 1 diabetes) or primary prevention (e.g., primary prevention). 
 
1     exp Aspirin/ or aspirin.mp. (57316) 
2     salicylic acid.mp. or exp Salicylic Acid/ (12354) 
3     salicylate.mp. or exp Salicylates/ (67574) 
4     diabetes mellitus.mp. or exp Diabetes Mellitus/ (385192) 
5     exp Diabetes Mellitus, Type 2/ or type 2 diabetes.mp. or exp Diabetes Mellitus, Type 1/ (175229) 
6     primary prevention.mp. or exp Primary Prevention/ (129138) 
7     1 or 2 or 3 (87752) 
8     4 or 5 (400493) 
9     7 and 8 (2474) 
10     6 and 7 (1251) 
11     9 or 10 (3511) 
12     (controlled clinical trial or randomized controlled trial or meta analysis).pt. (553258) 
13     (placebo* or random* or trial* or groups).ti,ab. (2468582) 
14     drug therapy.fs. (1822690) 
15     12 or 13 or 14 (3987797) 
16     11 and 15 (2069) 
17     limit 16 to humans (1900) 
 
Each part was specifically translated for searching alternative databases. 
Appendix 3 Reference list of included studies 
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Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321(3): 129-
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Appendix 4 Assessment of risk of bias 
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HOT + + + + + - +
PPP + + - - + + ?
WHS + ? + + + - +
POPADAD + + + + + + +
JPAD + + - + + + ?
JPPP + + - + + - ?
 
BMD, British male doctors; ETDRS, Early Treatment Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; IHD, 
ischaemic heart disease; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; JPPP, Japanese 
Primary Prevention Project; NR, not reported; PHS, Physicians’ Health Study; POPADAD, Prevention Of Progression of Arterial 
Disease And Diabetes; PPP, Primary Prevention Project; WHS, Women’s Health Study 
  
Appendix 5 Relative risks of major adverse cardiovascular events in participants with diabetes for 
aspirin intervention trials 
 
Overall (Random effects)
Overall (Fixed effects)
JPPP
JPAD
POPADAD
WHS
Study
ETDRS
HOT
PPP
86 / 2,445
68 / 1,262
105 / 638
58 / 514
Aspirin
Events / Participants
350 / 1,856
47 / 752
20 / 519
98 / 2,458
86 / 1,277
108 / 638
62 / 513
Placebo or control
Events / Placebo
379 / 1,855
54 / 749
22 / 512
0.90 (0.81, 0.99)
0.90 (0.81, 0.99)
0.89 (0.66, 1.18)
0.80 (0.58, 1.10)
0.97 (0.76, 1.24)
0.90 (0.63, 1.29)
RR (95% CI)
0.90 (0.78, 1.04)
0.87 (0.59, 1.26)
0.90 (0.50, 1.62)
Favours aspirin  Favours control or placebo 
1.5 .75 1.5 2.5
 
 
 
Study acronyms are provided in Appendix 4; CI, confidence interval (bars) 
Appendix 6 Relative risks of myocardial infarction in participants with diabetes for aspirin 
intervention trials 
 
Overall (Random effects)
Study
Overall (Fixed effects)
POPADAD
HOT
ETDRS
WHS
PHS
JPAD
PPP
Aspirin
Events / Participants
90 / 638
11 / 752
241 / 1,856
36 / 514
11 / 275
28 / 1,262
5 / 519
Placebo or control
Events / Participants
82 / 638
18 / 749
283 / 1,855
24 / 513
26 / 258
14 / 1,277
10 / 512
0.84 (0.64, 1.11)
RR (95% CI)
0.87 (0.76, 1.00)
1.10 (0.83, 1.45)
0.61 (0.29, 1.28)
0.82 (0.69, 0.98)
1.48 (0.88, 2.49)
0.40 (0.20, 0.79)
0.87 (0.40, 1.87)
0.49 (0.17, 1.40)
Favours aspirin  Favours control or placebo 
1.15 .25 .5 .75 1.5 2.5 5
 
 
Study acronyms are provided in Appendix 4; CI, confidence interval (bars) 
  
 
Appendix 7 Relative risks of coronary heart disease in participants with diabetes for aspirin 
intervention trials 
 
Overall (Random effects)
BMD
POPADAD
TPT
HOT
Overall (Fixed effects)
JPAD
Study
13 / 69
90 / 638
4 / 29
21 / 752
28 / 1,262
Aspirin
Events / Participants
6 / 32
82 / 638
6 / 39
27 / 749
35 / 1,277
Placebo or control
Events / Participants
0.98 (0.79, 1.21)
1.00 (0.42, 2.40)
1.10 (0.83, 1.45)
0.90 (0.28, 2.89)
0.77 (0.44, 1.36)
0.98 (0.79, 1.21)
0.81 (0.49, 1.33)
RR (95% CI)
Favours aspirin  Favours control or placebo 
1.15 .25 .5 .75 1.5 2.5 5
 
 
Study acronyms are provided in Appendix 4; CI, confidence interval (bars) 
  
Appendix 8 Relative risks of stroke in participants with diabetes for aspirin intervention trials 
 
 
Overall (Random effects)
POPADAD
JPAD
WHS
Overall (Fixed effects)
HOT
ETDRS
BMD
Study
TPT
PPP
37 / 638
28 / 1,262
15 / 514
20 / 752
92 / 1,856
3 / 69
Aspirin
Events / Participants
1 / 29
9 / 519
50 / 638
32 / 1,277
31 / 513
22 / 749
78 / 1,855
1 / 32
Placebo or control
Events / Participants
2 / 39
10 / 512
0.86 (0.69, 1.08)
0.74 (0.49, 1.12)
0.84 (0.53, 1.32)
0.46 (0.25, 0.85)
0.89 (0.74, 1.07)
0.91 (0.50, 1.64)
1.17 (0.87, 1.58)
1.39 (0.15, 12.86)
RR (95% CI)
0.67 (0.06, 7.06)
0.89 (0.36, 2.17)
Favours aspirin  Favours control or placebo 
1.05 .15 .25 .5 .75 1.5 2.5 5 7.5 15
 
 
Study acronyms are provided in Appendix 4; CI, confidence interval (bars) 
  
Appendix 9 Relative risks of cardiovascular disease mortality in participants with diabetes for aspirin 
intervention trials 
 
Overall (Random effects)
POPADAD
ETDRS
HOT
Overall (Fixed effects)
Study
PPP
JPAD
43 / 638
244 / 1,856
23 / 752
Aspirin
Events / Participants
10 / 519
1 / 1,262
35 / 638
275 / 1,855
26 / 749
Placebo or control
Events / Participants
8 / 512
10 / 1,277
0.94 (0.71, 1.26)
1.23 (0.80, 1.89)
0.87 (0.73, 1.04)
0.88 (0.51, 1.53)
0.91 (0.78, 1.06)
RR (95% CI)
1.23 (0.49, 3.10)
0.10 (0.01, 0.79)
Favours aspirin  Favours control or placebo 
1.05 .15 .25 .5 .75 1.5 2.5 5
 
 
 
 
Study acronyms are provided in Appendix 4; CI, confidence interval (bars) 
  
Appendix 10 Relative risks of all-cause mortality in participants with diabetes for aspirin intervention 
trials 
 
Overall (Random effects)
JPAD
Study
POPADAD
HOT
Overall (Fixed effects)
ETDRS
PPP
34 / 1,262
Aspirin
Events / Participants
94 / 638
40 / 752
340 / 1,856
25 / 519
38 / 1,277
Placebo or control
Events / Participants
101 / 638
36 / 749
366 / 1,855
20 / 512
0.94 (0.83, 1.05)
0.90 (0.57, 1.14)
RR (95% CI)
0.93 (0.71, 1.24)
1.11 (0.71, 1.72)
0.94 (0.83, 1.05)
0.91 (0.78, 1.06)
1.23 (0.69, 2.19)
Favours aspirin  Favours control or placebo 
1.5 .75 1.5 2.5 5
 
 
Study acronyms are provided in Appendix 4; CI, confidence interval (bars) 
Appendix 11 Relative risks of other cardiovascular outcomes in participants with diabetes for aspirin 
intervention trials 
 
 
Sudden coronary death
ETDRS
Random effects
Fixed effects
Fatal stroke
JPAD
POPADAD
ETDRS
Random effects
Fixed effects
Cardiovascular disease
PPP
Random effects
Fixed effects
Angina pectoris
PPP
JPAD
POPADAD
Random effects
Fixed effects
Transient ischemic attack
JPAD
PPP
POPADAD
Random effects
Fixed effects
Revascularization
PPP
POPADAD
Random effects
Fixed effects
Ischemic stroke
WHS
JPAD
Random effects
Fixed effects
CHD death
POPADAD
Random effects
Fixed effects
Nonfatal MI
JPAD
POPADAD
Random effects
Fixed effects
Nonfatal stroke
POPADAD
Random effects
Fixed effects
Hemorrhagic stroke
JPAD
Random effects
Fixed effects
Study
47 / 1,856
1 / 1,262
8 / 638
25 / 1,856
20 / 519
13 / 519
16 / 1,262
70 / 638
5 / 1,262
7 / 519
14 / 638
8 / 519
17 / 638
13 / 514
22 / 1,262
35 / 638
12 / 1,262
55 / 638
29 / 638
5 / 1,262
Aspirin
Events / Participants
67 / 1,855
5 / 1,277
9 / 638
25 / 1,855
22 / 512
16 / 512
21 / 1,277
78 / 638
8 / 1,277
10 / 512
20 / 638
10 / 512
24 / 638
29 / 513
24 / 1,277
26 / 638
9 / 1,277
56 / 638
41 / 638
3 / 1,277
Placebo or control
Events / Participants
0.70 (0.49, 1.01)
0.70 (0.49, 1.00)
0.70 (0.49, 1.00)
0.20 (0.02, 1.74)
0.89 (0.34, 2.30)
1.00 (0.58, 1.73)
0.91 (0.57, 1.44)
0.91 (0.57, 1.44)
0.90 (0.50, 1.62)
0.90 (0.50, 1.62)
0.90 (0.50, 1.62)
0.80 (0.39, 1.64)
0.78 (0.40, 1.52)
0.90 (0.66, 1.25)
0.87 (0.66, 1.13)
0.87 (0.66, 1.13)
0.63 (0.21, 1.93)
0.69 (0.27, 1.79)
0.70 (0.36, 1.39)
0.68 (0.42, 1.12)
0.68 (0.42, 1.12)
0.79 (0.31, 1.97)
0.71 (0.38, 1.33)
0.73 (0.44, 1.23)
0.73 (0.44, 1.23)
0.42 (0.22, 0.82)
0.93 (0.52, 1.66)
0.63 (0.29, 1.38)
0.66 (0.42, 1.01)
1.35 (0.81, 2.25)
1.35 (0.81, 2.25)
1.35 (0.81, 2.25)
1.34 (0.57, 3.19)
0.98 (0.68, 1.43)
1.03 (0.73, 1.45)
1.03 (0.73, 1.45)
0.71 (0.44, 1.14)
0.71 (0.44, 1.14)
0.71 (0.44, 1.14)
1.68 (0.40, 7.04)
1.68 (0.40, 7.05)
1.68 (0.40, 7.05)
RR (95% CI)
Favours aspirin  Favours control or placebo 
1.15 .25 .5 .75 1.5 2.5 5 7.5
 
Study acronyms are provided in Appendix 4; CI, confidence interval (bars) 
 
 
 
 
 
 
 
 
 
  
Appendix 12 Effects of aspirin therapy on myocardial infarction in participants with diabetes, 
according to various characteristics 
 
Location
Europe
North America
Other
Allocation concealment
Adequate
Unclear
Baseline CVD risk
High risk
Low risk
Aspirin dose (mg/day)
> 100
≤ 100
Compliance (%)
≥ 90
< 90
Treatment duration (years)
> 5
≤ 5
No. of events
> 150
≤ 150
Subgroup
95 / 1,157
288 / 2,645
39 / 2,014
134 / 3,171
288 / 2,645
95 / 1,157
327 / 4,659
252 / 2,131
170 / 3,685
327 / 4,659
95 / 1,157
126 / 1,152
296 / 4,664
331 / 2,494
91 / 3,322
Aspirin
Events / Participants
92 / 1,150
333 / 2,626
32 / 2,026
124 / 3,176
333/ 2,626
92 / 1,150
365 / 4,652
309 / 2,113
148 / 3,689
365 / 4,652
92 / 1,150
106 / 1,151
351 / 4,651
365 / 2,493
92 / 3,309
Placebo or control
Events / Participants
0.87 (0.42, 1.79)
0.82 (0.47, 1.42)
0.72 (0.42, 1.24)
0.88 (0.63, 1.25)
0.82 (0.47, 1.42)
0.87 (0.72, 1.79)
0.80 (0.56, 1.15)
0.62 (0.31, 1.23)
0.98 (0.72, 1.36)
0.80 (0.56, 1.15)
0.87 (0.42, 1.79)
1.18 (0.92, 1.50)
0.70 (0.53, 0.93)
0.93 (0.70, 1.24)
0.72 (0.43, 1.23)
RR (95% CI)
.932
.971
.721
.232
.721
.012
.454
Favours aspirin  Favours control or placebo 
1.25 .5 1.5 2.5
P-value*
 
The summary estimates presented were calculated using random effects models; CI, confidence interval (bars);*, 
P-value for meta-regression 
Appendix 13 Effects of aspirin therapy on stroke in participants with diabetes, according to various 
characteristics 
Location
Europe
North America
Other
Allocation concealment
Adequate
Unclear
Baseline CVD risk
High risk
Low risk
Aspirin dose (mg/day)
> 100
≤ 100
Compliance (%)
≥ 90
< 90
Duration (years)
> 5
≤ 5
No. of events
≥ 50
< 50
Subgroup
50 / 1,255
107 / 2,370
48 / 2,014
95 / 3,200
110 / 2,439
47 / 1,186
158 / 4,453
95 / 1,925
110 / 3,714
159 / 4,482
46 / 1,157
56 / 1,250
149 / 4,389
157 / 3,756
48 / 1,883
Aspirin
Events / Participants
63 / 1,221
109 / 2,368
54 / 2,026
116 / 3,215
110 / 2,400
62 / 1,189
164 / 4,426
79 / 1,887
147 / 3,728
166 / 4,465
60 / 1,150
84 / 1,222
142 / 4,393
160 / 3,770
66 / 1,845
Placebo or control
Events / Participants
0.77 (0.54, 1.12)
0.76 (0.31, 1.90)
0.87 (0.60, 1.24)
0.81 (0.63, 1.05)
0.82 (0.37, 1.79)
0.76 (0.53, 1.10)
0.86 (0.61, 1.22)
1.17 (0.87, 1.58)
0.75 (0.59, 0.95)
0.87 (0.63, 1.19)
0.76 (0.53, 1.11)
0.65 (0.47, 0.91)
1.03 (0.82, 1.28)
0.93 (0.69, 1.25)
0.71 (0.49, 1.03)
RR (95% CI)
.974
.708
.599
.019
.632
.026
.218
P-value*
Favours aspirin  Favours control or placebo 
1.25 .5 1.5 2.5 5
 
The summary estimates presented were calculated using random effects models; CI, confidence interval (bars);*, 
P-value for meta-regression 
Appendix 14 Effects of aspirin therapy on cardiovascular disease mortality in participants with 
diabetes, according to various characteristics 
 
Location
Europe
North America
Other
Allocation concealment
Adequate
Unclear
Baseline CVD risk
High risk
Low risk
Aspirin dose (mg/day)
> 100
≤ 100
Compliance (%)
≥ 90
< 90
Treatment duration (years)
≥ 5
< 5
No. of events
≥ 50
< 50
Subgroup
53 / 1,157
244 / 1,856
24 / 2,014
77 / 3,171
244 / 1,856
53 / 1,157
268 / 3,870
244 / 1,856
77 / 3,171
268 / 3,870
53 / 1,157
287 / 2,494
34 / 2,533
287 / 2,494
34 / 2,533
Aspirin
Events / Participants
43 / 1,150
275 / 1,855
36 / 2,026
79 / 3,176
275 / 1,855
43 / 1,150
311 / 3,881
275 / 1,855
79 / 3,176
311 / 3,881
43 / 1,150
310 / 2,493
44 / 2,538
310 / 2,493
44 / 2,538
Placebo or control
Events / Participants
1.23 (0.83, 1.82)
0.87 (0.73, 1.04)
0.39 (0.05, 3.06)
0.97 (0.59, 1.60)
0.87 (0.73, 1.04)
1.23 (0.83, 1.82)
0.80 (0.52, 1.25)
0.87 (0.73, 1.04)
0.97 (0.59, 1.60)
0.80 (0.52, 1.25)
1.23 (0.83, 1.82)
0.98 (0.71, 1.35)
0.76 (0.33, 1.79)
0.98 (0.71, 1.35)
0.76 (0.33, 1.79)
RR (95% CI)
.533
.793
.172
.793
.172
.639
.639
P-value*
Favours aspirin  Favours control or placebo 
1.25 .5 1.5 2.5 5
 
The summary estimates presented were calculated using random effects models; CI, confidence interval (bars);*, 
P-value for meta-regression 
Appendix 15 Effects of aspirin therapy on all-cause mortality in participants with diabetes, according 
to various characteristics 
 
Location
Europe
North America
Other
Allocation concealment
Adequate
Unclear
Baseline CVD risk
High risk
Low risk
Aspirin dose (mg/day)
> 100
≤ 100
Compliance (%)
≥ 90
< 90
Treatment duration (years)
≥ 5
< 5
No. of events
≥ 50
< 50
Subgroup
119 / 1,157
340 / 1,856
74 / 2,014
193 / 3,171
340 / 1,856
119 / 1,157
414 / 3,870
340 / 1,856
193 / 3,171
414 / 3,870
119 / 1,157
434 / 2,494
99 / 2,533
508 / 4,508
25 / 519
Aspirin
Events / Participants
121 / 1,150
366 / 1,855
74 / 2,026
195 / 3,176
366 / 1,855
121 / 1,150
440 / 3,881
366 / 1,855
195 / 3,176
440 / 3,881
121 / 1,150
467 / 2,493
94 / 2,538
541 / 4,519
20 / 512
Placebo or control
Events / Participants
0.98 (0.76, 1.26)
0.91 (0.78, 1.06)
0.98 (0.74, 1.28)
0.98 (0.81, 1.18)
0.91 (0.78, 1.06)
0.98 (0.76, 1.26)
0.93 (0.81, 1.06)
0.91 (0.78, 1.06)
0.98 (0.81, 1.18)
0.93 (0.81, 1.06)
0.98 (0.76, 1.26)
0.92 (0.80, 1.05)
1.02 (0.80, 1.30)
0.93 (0.82, 1.05)
1.23 (0.69, 2.19)
RR (95% CI)
.841
.557
.689
.557
.689
.459
.346
P-value*
Favours aspirin  Favours control or placebo 
1.5 1.5 2.5
 
The summary estimates presented were calculated using random effects models; CI, confidence interval (bars);*, 
P-value for meta-regression 
 
 
 
Appendix 16 Assessment of small study effects by funnel plots and Egger’s regression symmetry tests 
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Study acronyms are provided in Appendix 4; CI, confidence interval (bars). The dotted lines show 95% confidence intervals around the overall summary estimate calculated using a fixed effect model;; P-values for 
bias calculated using Egger’s test were 0.599; 0.597; 0.311; 0.462; 0.796; and 0.796 for major adverse cardiovascular events; myocardial infarction; coronary heart disease; stroke; cardiovascular disease mortality; and 
all-cause mortality 
